Wuhan General Group, Inc.
21.7.2021 15:18:14 CEST | ACCESS Newswire | Press release
CAPE TOWN, SA / ACCESSWIRE / July 21, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:
M2Bio Sciences Food & Beverage is pleased to announce the launch of the M2Bio 10mg CBD Dissolvable Powder Sachets. The sachets are the latest innovation from the Company's M2Bio brand portfolio of products, offering adults the opportunity to enjoy CBD their way. The sachet contains high-quality CBD isolate sourced from Oregon, USA. Each sachet contains 10mg of water-soluble CBD.
The convenient pre-packaged powder format makes it easy to mix the sachets contents into any beverage quickly and easily. The versatility of the product enables the consumer to enjoy premium CBD in a wide variety of settings and on any occasion of their choosing.
"The M2Bio CBD Sachets showcase the creativity, focus, and expertise of M2Bio's product development team and reinforces our company commitment to growth through innovation. Consumers who have tried our Medspresso™ CBD beverage range also enquired about CBD in its raw form. Offering the customers, the water-soluble CBD powder, allows them the flexibility to infuse it with other foods and beverages as well. Ultimately, we want to get as many people to experience the health benefits of CBD and this is a step in the right direction. We have developed a process and product that blend science and individual tastes to help adults explore new, personal CBD experiences," says Michael Sachar, CEO of M2Bio Sciences Food and Beverage.
Key features of the M2Bio CBD Sachets include the following:
- Customizable: Can easily be added to almost any beverage, transforming it into a CBD-infused drink in a matter of seconds.
- Rapid: M2Bio Sachets dissolve rapidly into beverages for a quick, straightforward CBD experience. In addition, the nano-emulsion formula provides improved absorption compared to traditional edibles and other delivery mechanisms.
- Discreet: M2Bio Sachets are odorless and mixes in clear to most drinks, making it a discreet addition. It also contains no added flavor.
- Co-branding opportunities: The nature of the product makes for a perfect co-branding opportunity with any beverage manufacturer, healthcare sector, retailers, hospitality, travel and tourism industries.
The sachets will be available to consumers in four formats:
- Single serve sachets - 10 mg CBD available at select retail outlets at POS.
- Pack of 5 sachets - 10 mg CBD x 5.
- Box of 60 Sachets - 10 mg CBD x 60. Monthly supply.
- Bulk Orders for B2B - 10 mg CBD x >2000 sachets.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™, and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".
Publicly traded company (OTC Pink:WUHN)
Website: www.m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio
Follow us on Instagram: https://www.instagram.com/m2bio.sciences
Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/656450/M2Bio-Sciences-Food-and-Beverage-Launches-CBD-Sachets
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI and MBDA Commit to Weapons Collaboration21.7.2026 16:00:00 CEST | Press release
Companies Will Integrate SPEAR Onto MQ-9B and Gambit 6 SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and MBDA have announced a commitment to integrate the European missile-maker's SPEAR precision strike weapons onto new aircraft built by the American uncrewed aircraft manufacturer. GA-ASI President David R. Alexander and MBDA UK Managing Director Chris Allam signed a memorandum of understanding that outlined the agreement at the Farnborough International Airshow 2026. The companies will work together to ensure the MQ-9B remotely piloted aircraft and Gambit 6 collaborative combat aircraft (CCA) can carry and use the SPEAR weapons. "We've built an excellent business relationship with MBDA as part of the integration of the Brimstone missile onto the UK's Protector," said Mr. Alexander. "So, working with MBDA to enable SPEAR on our broader MQ-9B line, and our Gambit CCA, feels like a very natural extension of our partnership." Protect
CHAR Tech Welcomes France's Regulatory Advance Opening Biogas Certificate Support to Pyrolysis21.7.2026 14:00:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 21, 2026 / (TSXV:YES)(OTC PINK:CTRNF)(FSE:68K) France proposes opening its flagship renewable gas support scheme (the CPB) to pyrolysis, putting CHAR Tech's HTP technology on the same footing as established production routes in one of Europe's largest gas markets Directly strengthens the HTP project pipeline being developed in France by CHAR Tech's partner GazoTech GazoTech's lead project, Bio-Méthane Provence, is being developed to deploy CHAR Tech's HTP platform to process 115,000 tonnes of recovered wood annually, producing 230 GWh (828,000 GJ) of RNG plus 12,000 tonnes of biocarbon, targeting commercial operations in H2 2029 CHAR Technologies Ltd. ("CHAR Tech" or "the Company"), a leader in sustainable biomass energy solutions, today welcomed a significant regulatory development in France that, if adopted, would open the country's flagship long-term support mechanism for renewable gas to pyrolysis-based production. The development materially str
Fermi Announces Second Quarter 2026 Earnings Release and Call Date20.7.2026 22:30:00 CEST | Press release
Fermi to host earnings call on August 13, 2026 DALLAS, TX / ACCESS Newswire / July 20, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that it plans to release second quarter 2026 financial results at 7 a.m. Eastern Time / 12 p.m. British Time on Thursday, August 13, 2026. This announcement will be followed by an earnings conference call at 9 a.m. Eastern Time / 2 p.m. British Time. The Company's earnings release and supplemental information will be posted to the Investors section of the Company's website prior to the conference call. To join the live conference call, dial 888-506-0062 in the U.S. or +1 973-528-0011 internationally approximately 15 minutes prior to the scheduled start time and refer to conference code 587288. The call will also be webcast in a listen-only mode and can be accessed through the Investor Relations Events & Presentations page of Fermi's website. A replay of the webcast will be available for
GA-ASI and KONGSBERG Advance JSM Integration for MQ-9B20.7.2026 12:05:00 CEST | Press release
Companies Bring Joint Strike Missile Weapon System to Leading Uncrewed Platform SAN DIEGO, CA / ACCESS Newswire / July 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and KONGSBERG Gruppen ASA (KONGSBERG) completed the System Requirements Review (SRR) and Preliminary Design Review (PDR) for the integration of the Joint Strike Missile (JSM) weapon system onto MQ-9B. This design and integration effort is a jointly funded project by both companies aimed at providing long-range strike capability for MQ-9B and its customers. These reviews were successfully completed in Kongsberg, Norway, on June 30. MQ-9B is an industry-leading uncrewed aircraft system (UAS) manufactured by GA-ASI and includes the SkyGuardian® and SeaGuardian® models. KONGSBERG produces the JSM, a best-in-class weapon system for use against high-priority targets. "We recognize the value JSM brings to our MQ-9B platform," said Niki Johnson, GA-ASI Vice President, International Capture and Government Affairs. "
GA-ASI Completes Qualification Testing for UK Protector Weapons20.7.2026 12:00:00 CEST | Press release
Concludes 6-Year U.S. and U.K. Governmental and Industry Collaboration SAN DIEGO, CA / ACCESS Newswire / July 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has completed weapons testing for the Royal Air Force's (RAF) Protector RG Mk1 Remotely Piloted Aircraft, qualifying both the Paveway IV laser-guided bomb and the Brimstone 3 air-to-surface missile for launch from GA-ASI's MQ-9B aircraft. Testing was completed on June 18 at GA-ASI's facilities in Southern California and marked the first time that GA-ASI has taken the lead role in completing weapons qualification for a customer. The qualification testing was conducted under UK Ministry of Defence approval and met all requirements for certification of the safe carriage and release of weapons. "The Royal Air Force is our MQ-9B launch customer and we're here to support them in any way we can," said GA-ASI President David R. Alexander. "Leading the qualification test was a unique experience and we're excited to complete
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom